Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: Study protocol for a randomized controlled trial (MSC-BPD Trial)

**CURRENT STATUS:** Accepted

Xian Wu  
Chongqing Medical University Affiliated Children's Hospital  
*ORCiD: 0000-0002-4466-5122*

Yunqiu Xia  
Chongqing Medical University Affiliated Children's Hospital

Ou Zhou  
Chongqing Medical University Affiliated Children's Hospital

Yan Song  
Chongqing Medical University Affiliated Children's Hospital

Xianhong Zhang  
Chongqing Medical University Affiliated Children's Hospital

Daiyin Tian  
Chongqing Medical University Affiliated Children's Hospital

Qubei Li  
Chongqing Medical University Affiliated Children's Hospital

Chang Shu  
Chongqing Medical University Affiliated Children's Hospital

Enmei Liu  
Chongqing Medical University Affiliated Children's Hospital

Xiaoping Yuan  
Chongqing Medical University Affiliated Children's Hospital

Ling He  
Chongqing Medical University Affiliated Children's Hospital
Chengjun Liu
Chongqing Medical University Affiliated Children's Hospital

Jing Li
Chongqing Medical University Affiliated Children's Hospital

Xiaohua Liang
Chongqing Medical University Affiliated Children's Hospital

Ke Yang
Chongqing Medical University Affiliated Children's Hospital

Zhou Fu
Chongqing Medical University Affiliated Children's Hospital

Lin Zou
Chongqing Medical University Affiliated Children's Hospital

Lei Bao
Chongqing Medical University Affiliated Children's Hospital

Jihong Dai  danieljh@163.com
Corresponding Author

DOI:
10.21203/rs.2.381/v3

SUBJECT AREAS
General Medicine

KEYWORDS
bronchopulmonary dysplasia, human umbilical cord-derived mesenchymal stem cells, clinical trial, protocol
Abstract

Background: Bronchopulmonary dysplasia (BPD) is a complex lung pathological lesion secondary to multiple factors and one of the most common chronic lung diseases with a poor prognosis, especially in preterm infants. However, effective therapies for this disease are lacking. Stem cell therapy is a promising way to improve lung injury and abnormal alveolarization, and the human umbilical cord (hUC) is a good source of mesenchymal stem cells (MSCs), which have demonstrated efficacy in other diseases. We hypothesized that intravenous allogeneic hUC-MSCs are safe and effective for severe BPD.

Methods: The MSC-BPD trial is a randomized single-center open-label dose-escalation phase II trial designed to investigate the safety and efficacy of hUC-MSCs in children with severe BPD. In this study, 72 patients will be enrolled and randomly divided into two intervention groups and one control group. Patients in the intervention groups will receive a low dose of hUC-MSCs (n = 24; 2.5 million cells/kg) or a high dose of hUC-MSCs (n = 24; 5 million cells/kg) in combination with traditional supportive treatments for BPD. The patients in the control group (n = 24) will be treated with traditional supportive treatments alone without hUC-MSCs. The primary outcome measures will be cumulative duration of oxygen therapy. Follow-up assessments will be performed at 1, 3, 6, 12, and 24 months post-intervention, and the key outcome during follow-up will be changes on chest radiography. Statistical analyses will evaluate the efficacy of the hUC-MSC treatment.

Discussion: This will be the first randomized controlled trial to evaluate the safety and efficacy of intravenous hUC-MSCs in children with severe BPD. Its results will provide a new evidence-based therapy for severe BPD.

Background
Bronchopulmonary dysplasia (BPD) is a common chronic lung disease whose incidence is increasing annually, especially in this time of the two-child policy in China [1,2]. Patients with BPD usually have ventilator or oxygen dependence during the early stage of the disease [3]. Most patients can gradually withdraw from the ventilator or stop oxygen treatment at different times depending on disease severity, but abnormalities in pulmonary structure and lung function may last until late childhood even adulthood, especially in those who are diagnosed as severe BPD according to the diagnostic criteria of the National Institute of Child Health and Human Development (NICHD) [4, 5]. The mortality of overall BPD patients is about 15% [6]; nevertheless, the mortality rate of severe BPD reaches 41%, creating an enormous threat to the health of these children [4, 7]. More than 50% of survivors with BPD experience hospital readmission for repeated lower respiratory infections in the first year or two, which causes serious economic and labor burdens on families [4, 8]. Although surfactant treatment [9], prenatal steroid usage [1, 10], ventilator strategies [11], and improved nutrition [12] are used in BPD patients, effective therapies are lacking [14]. Therefore, identifying novel effective therapies for severe BPD in children is urgent and significant.

In recent years, the rapid development of stem cell technology and regenerative medicine has identified stem cells as potential treatments for various refractory diseases, which are difficult to treat by traditional medical methods, such as degenerative diseases, cancer, and tissue damage [15–17]. Mesenchymal stem cells (MSCs) are a class of adult stem cells derived from the mesoderm with characteristics of non-tumorigenic, low immunogenicity, and powerful paracrine function, and can be isolated from several sources, including bone marrow, human umbilical cord (UC), adipose tissue, amniotic fluid, and other tissues [18, 19]. Among them, hUC-derived mesenchymal stem cells (hUC-MSCs) are useful in clinical application because they are easy to obtain, more proliferative, and have more powerful
paracrine function than any other sources; they are effective at relieving lung inflammation, fibrosis, angiogenesis, and apoptosis [20–24]. Interestingly, the therapeutic potential of hUC-MSCs in several animal pulmonary diseases models, including BPD, acute lung injury, and idiopathic pulmonary fibrosis, were confirmed [22, 25, 26]. Approximately 75% of hUC-MSCs reportedly accumulate in the microvessels of the lungs [27]. Hence, the therapeutic potential of hUC-MSCs for severe BPD in children requires investigation.

A multicenter dose-escalation phase I clinical trial (NCT01775774) investigated the safety and efficacy of bone marrow-derived MSCs for moderate to severe acute respiratory distress syndrome (ARDS) in adults without any adverse events (AEs) related to infusion reported, which had potential efficacy [28]. The study reported that hUC-MSC treatment was safe in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (NCT00683722) [29]. Another phase I trial reported treating 9 BPD patients in Korea with hUC blood-derived mesenchymal stem cells (hUCB-MSCs) (NCT01297205) [30]. The follow-up data from this study showed the safety of hUCB-MSC administration and the ability to reduce the level of profibrotic factors in tracheal aspirates [31]. Despite these data indicating the safety of MSC infusions for patients with pulmonary diseases, the limited sample size and lack of appropriate controls in those trials were insufficient to show the efficacy of MSC treatment. A large sample size of phase II trials with matched controls is required to further investigate hUC-MSC safety and efficacy. Based on the previous promising findings, we designed an MSC-BPD trial to evaluate the safety and efficacy of the intravenous infusion of hUC-MSCs in children with severe BPD.

Methods

Study objectives

The goal of this clinical trial is to test the safety and efficacy of hUC-MSCs in children with severe BPD. There are three specific objectives:
Evaluate the long-term safety and efficacy of intravenous hUC-MSCs in children with severe BPD; Test the hypothesis that the administration of hUC-MSCs can reduce the duration of mechanical ventilation and oxygen and improve impairment of the pulmonary structure in children with severe BPD; and Explore the potential therapeutic mechanism of hUC-MSCs for severe BPD.

**Study design and setting**

The MSC-BPD trial (registered at www.clinicaltrials.gov [no. NCT03601416]) is a randomized single-center dose-escalation phase II trial aiming to evaluate the safety and efficacy of hUC-MSCs in a total of 72 children with severe BPD. A study flow chart of the trial is shown in Fig. 1. The study protocol will be reported based on SPIRIT guidelines (Additional file 1).

This trial will be conducted at the Children’s Hospital of Chongqing Medical University (CHCMU) in Chongqing, China.

**Sample size and calculation**

The sample size of this phase II randomized controlled trial was calculated by power analysis using the Power and Sample Size online calculator (http://powerandsamplesize.com/). The trial is designed to investigate the hypotheses of two interventions compared to control, but it is not powered to test differences between the two intervention groups. The larger of the two numbers is the sample size of this trial. The primary outcome measure is the change in the cumulative duration of oxygen therapy. The cumulative mean duration of severe BPD is reportedly 90 ± 15 d [4, 13]. This trial is powered to identify differences of 15% (from 90 d in the control group to 77 d in the low dose groups) and 20% (from 90 d in the control group to 72 d in the high dose groups) in participants who accept the hUC-MSC intervention. Meanwhile, the power is set at 0.8, type I error $\alpha$ is 0.05, and type II error $\beta$ is 0.20. The calculated sample size is 21 for each group. To account for the possibility of 10% of patients being lost to follow-up, the final sample size will be 24 and the total size will be 72.
Participants

Patient and public involvement

The participants will not be involved in the development of the trial including the study design, recruitment, and conduct, selection of research question, and outcome measures. The participation will be voluntary and the participants will have freedom to participate or withdraw from this trial at any time throughout the study. The participants’ privacy will be protected.

Participants will be enrolled in this study according to the inclusion and exclusion criteria (Table 1). The parents or guardians of all participants will provide the written informed consent form approved by the Ethics Committee of Stem Cell Clinical Research of CHCMU.

Inclusion and exclusion criteria

The inclusion and exclusion criteria are listed in Table 1. Participants will be 0–1 year of age. The diagnostic criteria and BPD severity gradation refers to the criteria established by the NICHD workshop [5]. The Silverman and Andersen score is used to assess the severity of abnormal respiratory manifestations [32].

Recruitment

Patients can only be enrolled in this study after passing the citywide consultation resolution and signing the informed consent form.

Participants will be recruited from three sources. First, the parents of potentially eligible hospitalized patients diagnosed with severe BPD will be approached and asked to join this study. Second, physicians will generate lists of patients with a diagnosis of BPD who were discharged within 1 year from the electronic medical records of CHCMU. Investigators or physicians will contact the patients’ parents by phone or mail them a research leaflet and recruitment letter. Third, physicians will post study flyers at the outpatient department, the official website, and the WeChat public platform of CHCMU for those diagnosed with
severe BPD at other hospitals. If the parents of these patients with severe BPD are interested in this research, we will initiate the screening process.

A multidisciplinary consultation will be held to confirm whether these potential participants meet the general diagnostic criteria of BPD as well as the inclusion and exclusion criteria. The consultation will consist of a neonatologist, a respiratory physician, a radiologist, a laboratory physician, a Department of Critical Care Medicine expert, stem cell treatment center researchers, and medical department staff. If more than 80% experts agree on the hUC-MSCs treatment, these patients will be viewed as potential participants. The researcher will then arrange a meeting to communicate with the legal representative or parents about the clinical trial research detail and sign the written informed consent form.

The following details of the clinical trial will be fully explained to the patients’ guardians as follows: (1) study purpose; (2) research background; (3) number of participants and duration of their participation; (4) study procedures; (5) potential discomfort and risks of treatment; (6) expected benefits; (7) protection of confidentiality and privacy; and (8) their participation is voluntary. Each patient’s legal representative or parents will sign the informed consent form after all the items above are fully understood. After that, the patients’ baseline characteristics will be recorded by the clinicians (Table 2).

Randomization and blinding

Participants will be randomized into three groups in a 1:1:1 ratio after collection of the baseline data. The allocation sequence will be generated and sent to the investigators by a statistician. Participants will not be blinded during the phase II trial and the patients in the control group will not be given hUC-MSC treatment.

Intervention

The hUC-MSCs produced by Ever Union Biotechnology Co. Ltd. (EUBIO) are transported to
the ward on the infusion day. The hUC-MSCs are suspended in 0.9% normal saline. In addition to inspecting the quality of the hUC-MSC product by EUBIO, the staff of the stem cell center in CHCMU will confirm the viability and quality of the hUC-MSC product before the infusion.

There is currently no effective therapy for BPD patients, who are often given traditional supportive treatments such as nutritional support, fluid restriction, and respiratory support (including ventilator support and oxygen supply) so all participants will be given traditional supportive treatments to ensure safety. Thus, the intervention groups will be given the traditional supportive treatments and extra low- or high-dose hUC-MSC infusion and the control group will be given only the traditional supportive treatment. Participants will be unable to use glucocorticoids 3 days before or after the hUC-MSC treatment.

A total of 72 patients in the intervention groups will be randomized in a 1:1:1 pattern to receive low-dose hUC-MSCs (n = 24; 2.5 million cells/kg) or high-dose hUC-MSCs (n = 24; 5 million cells/kg) in combination with traditional supportive treatments or traditional supportive treatments alone (n = 24).

**Withdrawal**

Discontinuation may occur due to participant death, severe adverse effects (SAEs), other serious disease limiting participation, or study withdrawal requested by the guardian. If the participant withdraws from the trial, the reason for the withdrawal and all the results of observations will recorded in detail. Meanwhile, a new participant will be enrolled in the trial to replace the withdrawn subject.

**Adverse events**

AEs are defined as adverse medical events that occur after the subjects or their guardians provide written informed consent until the end of the study visit. AEs include abnormal laboratory results, symptoms, or diseases. All AEs will be recorded on a Case Report Form
(CRF) and the researcher should provide comprehensive clinical reports. Once AEs occur, we will follow the principle of “the first priority of the participants,” take the necessary treatment according to the patients’ specific situation, and decide whether to suspend the clinical research. The main investigator should immediately inform the Scientific Research Office, Medical Service, and Ethics Committee of CHCMU. The SAE report should be submitted in writing within 24 hours, while a follow-up SAE report should be submitted to the Human Research Ethics Committee.

An insurance policy will be prepared for all participants, who will be provided with ancillary and post-trial care in the case of injury or death as a result of their participation in the trial.

**Outcome evaluation**

The outcome measures and their time frames of this trial are listed in Table 3. The primary endpoint is the cumulative duration of oxygen therapy, i.e. the duration from starting to stopping oxygen treatment.

The secondary endpoints include the safety and efficacy outcomes. The safety of the study will be assessed by the number of AEs including SAEs, acute infusion-associated AEs (AIA-AEs) and late infusion-associated AEs (LIA-AEs). SAEs include death, malignant cardiac event (new ventricular tachycardia, ventricular fibrillation, or asystole, cardiac arrest), acute pulmonary embolism, stroke, anaphylactic shock, acute transplant rejection, and any other diseases extending the hospital stay. AIA-AEs include fever, general allergic reaction (rash, edema, erythema, pale), infection at the injection site, vital signs changes, laboratory test changes (indicators of liver and kidney function, cardiac markers, indicators of hematology and immunity, markers of hepatitis/syphilis/HIV/tuberculosis, and urinalysis). LIA-AEs include tumorigenic events (tumor formation) and teratogenic events.

The efficacy endpoints are as follows: duration of oxygen therapy, duration of invasive
mechanical ventilation, duration of noninvasive mechanical ventilation, the first time stopping the supplemental oxygen, rate of re-oxygen supplement, blood oxygen saturation, chest radiography changes, pulmonary function changes, mortality, number of hospital readmissions, and preterm birth complications.

**Follow-up procedures**

Follow-up assessments will be performed at 1, 3, 6, 12, and 24 m after the hUC-MSC injection (Table 2). The five follow-up points will be conducted through telephone and outpatient contact. The first two follow-ups will be performed at 1 and 3 m after the hUC-MSC treatment by phone to ask the parents of the condition of their child(ren). The details of the phone interview are shown in Table 4. The next three follow-ups will be performed at 6, 12, and 24 m at outpatient visits as shown in Table 5. The key outcome during follow-up will be changes on chest radiographs.

**Safety monitoring**

The independent Data and Safety Monitoring Board (DSMB) will supervise safety during the trial. The members of DSMB are independent of the sponsor and trial investigators and have no competing interests. The DSMB will review and evaluate clinical safety and efficacy data collected according to the specified time intervals in the protocol. If the threshold of the safety data exceeds a predefined threshold, the DSMB will be notified. Furthermore, the DSMB will conduct the interim analysis of all AE occurrences every 6 months during the study. Only the data managers and study designers have access to the data in the trial. The data will be locked by the data management team when the trial is completed. All of the data will be provided to the DSMB. If the trial is terminated earlier than the expected end date, the DSMB will contribute to that decision.

**Data collection**

The data generated during the trial will be recorded in the original medical record and the
CRF. The quality control personnel will check the consistency of the CRF data with the original record to ensure that the data are accurately entered into the CRF. There are nine data collection points: baseline, 1 d, 3 d, 7 d, 1 m, 3 m, 6 m, 12 m, and 24 m (Table 2). Within 3 days after completion of the data collection, the research records will be submitted to the research leader for review and all data will be submitted to the project leader within 10 days. Next, the auditor will review each original research record to confirm that the clinical trial data records are timely, precise, and standardized. Data checks and entries will then be disposed by the statistical data manager and analyzed by the statisticians.

The data of this trial will be disseminated through national and international conferences and peer-reviewed publications. Our data set will be available after the trial’s completion.

**Statistical analysis**

SPSS version 17 (SPSS Inc., Chicago, IL, USA) statistical analysis software will be used to analyze the data in the study. Significant differences will be considered at an α level of 0.05.

Normally distributed continuous variables will be reported as mean and standard deviation (SD) groups compared using the t-test. Continuous variables that do not satisfy the normal distribution will be expressed as X50% (X25%, X75%) and compared between groups using the Wilcoxon rank sum test. Categorical variables will be reported as number (n) and percentages of the total (%), while the χ² test will be used to test differences between two groups.

Baseline among groups will be compared using analysis of variance (ANOVA). The primary outcome, duration of oxygen therapy, will be analyzed by one-way ANOVA, followed by the Bonferroni test. Outcomes including duration of mechanical ventilation, pulmonary function tests, and quantitative scores of chest radiography changes will be compared
using ANOVA. Mortality, re-oxygen supplementation, and hospital readmission rates will be tested by the $\chi^2$ test, while 24-month mortality will be analyzed by Kaplan-Meier curves.

**Discussion**

At present, apart from symptomatic supportive therapy, there is no effective treatment for severe BPD patients [33]. Therefore, identifying new treatment methods to improve the prognosis of premature infants is imperative. Studies have shown that stem cell therapy can significantly improve neonatal hyperoxic lung injury [34, 35], suggesting that stem cell transplantation may be a promising treatment for severe BPD.

The intratracheal administration of MSCs in premature infants at high risk of BPD has been investigated in several small uncontrolled studies registered at ClinicalTrials.gov. These studies aim to investigate whether local regional hUC-MSC delivery to the airway is safe and potentially effective and could prevent BPD in premature infants. However, most patients with severe BPD only receive oxygen treatment when a medical ventilator was no longer used. Intratracheal hUC-MSC treatment is difficult to administer to patients under these circumstances. Hence, intravenous administration may be a better choice. Recent studies have shown that the intravenous administration of MSCs was safe and had some potential efficacy in several lung diseases, including ARDS and COPD [28, 29], but there are few reports on BPD. Based on these studies, the intravenous administration of MSCs is expected to be a worthwhile option for patients with severe BPD. Considering that hUC-MSCs are a main source in clinical trials, this trial aims to evaluate whether allogeneic hUC-MSC therapy is safe and effective in severe BPD patients with a matched control. We hypothesized that this research will provide data showing that hUC-MSC administration is safe and feasible for severe BPD patients.

A variety of studies on hUC-MSC clinical trials performed a dose-escalation of hUC-MSCs of
0.5–5 million cells/kg in adults through intravenous infusions; the largest dose of a few trials reached 10 million cells/kg [28, 29, 36, 37]. However, few trial reports explored the effect of different doses of hUC-MSCs in children’s diseases, especially in those with severe BPD. Thus, we will conduct a dose-escalation trial of intravenous hUC-MSCs for the treatment of severe BPD patients. Considering that the features of premature infants include low weight and immature organ function, we determined a maximum hUC-MSC dose of 5 million cells/kg.

Although this planned trial cannot use a high-quality randomized controlled trial design since it is an open-label trial, it has several advantages. First, this is a first trial to investigate the therapeutic rather than preventive effects of hUC-MSCs in children with severe BPD. Second, this study will explore a dose-escalation of hUC-MSC treatment through intravenous administration. Third, if we can observe some efficacy, our results may broaden our understanding of hUC-MSC effects in BPD and provide a basis for treating patients with severe BPD. However, if there are no obvious effects, our study will also have important clinical implications for pediatric refractory diseases. As several kinds of patients currently receive MSC therapy for which potential efficacy has been reported [30], randomized trials are lacking to prove its safety or efficacy.

Overall, the MSC-BPD Trial is a vital and exploratory step in the investigation of a new evidence-based therapy for a large number of pediatric BPD patients.

Trial Status

Start date: July 2019.

Expected end date: December 2021.

Status at time of submission of this article: not yet recruiting.

Declarations
Abbreviations

AEs, adverse events; AIA-AEs, acute infusion–associated adverse events; ANOVA, analysis of variance; ARDS, acute respiratory distress syndrome; BPD, bronchopulmonary dysplasia; CHCMU, Children’s Hospital of Chongqing Medical University; COPD, chronic obstructive pulmonary disease; DSMB, Data and Safety Monitoring Board; EUBIO, Ever Union Biotechnology Co. Ltd.; hUC-MSCs, human umbilical cord mesenchymal stem cells; LIA-AEs, late infusion–associated adverse events; MSCs, mesenchymal stem cells; NICHD, National Institute of Child Health and Human Development; SAEs, severe adverse events; UC, umbilical cord.

Acknowledgements

We would like to acknowledge the entire staff of the Department of Respiratory Medicine and Neonatology of the Children’s Hospital of Chongqing Medical University for their help and great efforts. We also would like to acknowledge patient advisers for their support.

Funding

This trial is partially supported by the National Nature Science Foundation of China (NSFC, 81670018, 81570142, 81870126), Key project from Chinese Ministry of Science and Technology (2016YFA0101300) who had no role in the design of the study and will have no role in the execution of the trial, or the analyses of the data, or the decision to submit the results.

Availability of data and materials

All the data in the trial will be available for anyone who wants to access the data following publication.

Authors’ contributions

ZF and LZ were the principal investigators of this MSC-BPD trial and coordinated the entire clinical trial. JHD, LB, YS, LH, CJL, JL, XHL, and KY contributed to the study design and
guided the study’s implementation. XW was involved in writing the protocol and editing the manuscript. XW, YQX, and OZ will be involved in setting up the trial and collecting the data. XHL will be responsible for the data integrity and analysis.

**Ethics approval and consent to participate**

The study had been approved by the Ethics Committee of Stem Cell Clinical Research of the Children’s Hospital of Chongqing Medical University with number 4/2018 on April 14, 2018. Participants’ parents or the legal guardian(s) will be informed about the potential risks, expected benefits, rights and responsibility of the study before signing informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

None declare that they have competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published map.

**Author details**

1 Pediatric Research Institute, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China.

2 Chongqing Key Laboratory of Pediatrics, China; China International Science and Technology Cooperation Base of Child Development and Critical Disorders, 400014, China.

3 Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing, 400014, China.

4 Department of Respiratory Medicine, Children’s Hospital of Chongqing Medical University, Chongqing, 400014, China.
References

1. Bhandari A, Panitch H. An update on the post-NICU discharge management of bronchopulmonary dysplasia. Semin Perinatol. 2018; 42(7): 471–477.

2. Geenongh A. Long term respiratory outcomes of very premature birth (<32 weeks). Semin Fetal Neonatal Med. 2012; 17(2): 73–76.

3. Principi N, DiPietro GM, Esposito S. Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies. J Transl Med. 2018; 16(1): 36.

4. Landry JS, Chan T, Lands L, Menzies D. Long-term impact of bronchopulmonary dysplasia on pulmonary function. Can Respir J. 2011; 18(5): 265–70.

5. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163 (7): 1723-9.

6. Payne NR, LaCorte M, Karna P, Chen S, Finkelstein M, Goldsmith JP, et al. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. J Pediatr. 2006; 118: S73-7.
7. Bhutta AZ, Yusuf K. Neonatal respiratory distress syndrome in Karachi: Some epidemiological considerations. Paediatr Perinat Epidemiol. 1997; 11: 37-43.

8. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, et al. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. J Pediatr. 2004; 144(6): 799-803.

9. Iyengar A, Davis JM. Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. Front Pharmacol. 2015; 6: 12.

10. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2017; 10: CD002058.

11. Keszler M, Sant’Anna G. Mechanical ventilation and bronchopulmonary dysplasia. Clin Perinatol. 2015; 42(4): 781-96.

12. Meyer S, Gortner L. Early posnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology. 2014; 105(3): 182-188.

13. Vom Hove M, Prenzel F, Uhlig HH, Robel-Tillig E. Pulmonary Outcome in Former Preterm, Very Low Birth Weight Children with Bronchopulmonary Dysplasia: A Case-Control Follow-Up at School Age. J Pediatr. 2014;164(1):40-45.e4.

14. Higgins RD, Jobe AH, Koso-Thomas M, Bancelari E, Viscardi RM, Hartert TV, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr. 2018; 197: 300-308.

15. Gupta N, Henry RG, Strober J, Kang SM, Lim DA, Bucci M, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012; 4(155): 155ra137.
16. Ayuzawa R, Doi C, Rachakatla RS, Pyle MM, Maurya DK, Troyer D, et al. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett. 2009; 280(1): 31–7.

17. Antunes MA, Laffey JG, Pelosi P, Rocco PR. Mesenchymal stem cell trials for pulmonary diseases. J Cell Biochem. 2014; 115: 1023–32.

18. Bianco P. “Mesenchymal” stem cells. Annu Rev Cell Dev Biol. 2014; 30: 677–704.

19. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008; 2(4): 313–9.

20. Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015; 24(3): 339–47.

21. Jungebluth P, Luedde M, Ferrer E, Luedde T, Vucur M, Peinado VI, et al. Mesenchymal stem cells restore lung function by recruiting resident and non-resident proteins. Cell Transplant. 2011; 20: 1561–74.

22. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin induced lung injury. Am J Pathol. 2009; 175: 303–13.

23. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010; 28: 2229–38.

24. Chang YS, Ahn SY, Jeon HB, Sung DK, Kim ES, Sung SI, et al. Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hypoxic lung injury. Am J Respir Cell Mol Biol. 2014; 51 (3): 391–9.

25. Chen Hou, Danyi Peng, Li Gao, Tian D, Dai J, Luo Z, et al. Human umbilical cord-derived mesenchymal stem cells protect from hypoxic lung injury by ameliorating aberrant elastin remodeling in the lung of O2-exposed newborn rat. Biochem Biophys
26. Hua Zhu, Yi Xiong, Yunqiu Xia, Zhang R, Tian D, Wang T, et al. Therapeutic effects of human umbilical cord-derived mesenchymal stem cells in acute lung injury mice. Sci Rep. 2017; 7: 39889.

27. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015; 16(1): 51–66.

28. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015; 3(1): 24–32.

29. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013; 143(6): 1590–1598.

30. Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 2014; 164(5): 966–972.e6.

31. Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr. 2017; 185: 49-54.e2.

32. Silverman WA, Andersen DH. A controlled clinical trial of effects of water mist on obstructive respiratory signs, death rate and necropsy findings among premature infants. J Pediatr. 1956; 17(1): 1–10.

33. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007; 357: 1946-55.

34. Chang YS, Choi SJ, Ahn SY, Sung DK, Sung SI, Yoo HS, et al. Timing of umbilical cord
blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS ONE. 2013; 8: e52419.

35. Pierro M, Ionescu L, Montemurro T, Vadivel A, Weissmann G, Oudit G, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax. 2012; 68: 475-84.

36. Wang L, Li J, Liu H, Li Y, Fu J, Sun Y, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013; 28 Suppl 1: 85-92.

37. He X, Ai S, Guo W, Yang Y, Wang Z, Jiang D, et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: a phase 1 clinical trial. Transl Res. 2018; 199: 52-61.

Tables

Table 1. Inclusion and exclusion criteria for participants with severe BPD

| Inclusion criteria |
|--------------------|
| 1. Participants who are male or female and whose age is 0 ~ 1 year old. |
| 2. Participants who are diagnosed as severe BPD according to diagnostic criteria of BPD made by the National Institute |
| 3. Participants who have abnormal respiratory manifestations and the Silverman Anderson score is more than 3 points. |
| 4. Written informed consent signed by a legal representative or a parent. |

| Exclusion criteria |
|--------------------|
| 1. Participants whose age is more than 1 year old. |
| 2. Participants who have no signs of dyspnea or BPD related changes in pulmonary imaging, such as central apnea or dia |
| 3. Participants who have concurrent cyanotic or acyanotic congenital heart diseases, except for patent ductus arteriosus, |
| 4. Participants whose important laboratory test (liver and kidney functions test, cardiac markers, hematology and immun the normal value. |
| 5. Participants who have severe pulmonary hypertension confirmed by cardiac ultrasound at the time of assessment. |
| 6. Participants who have severe respiratory tract malformation, such as pierre-robin syndrome, tracheobronchomalacia, v pulmonary emphysema, pulmonary sequestration, congenital pulmonary dysplasia, congenital pulmonary cyst, congenit |
| 7. Participants who have severe chromosome anomalies (such as Edward syndrome, Patau syndrome, Down syndrome) c hereditary diseases. |
| 8. Participants who have severe congenital infection such as Herpes Simplex, Toxoplasmosis, Rubella, Syphilis, AIDS, etc. |
| 9. Participants who have severe active infection when CRP> 30mg / dL, or suffer sepsis or septic shock. |
| 10. Participants who are going to have surgery within 72 hours before/after this study hUC-MSCs administration. |
| 11. Participants who have surfactant administration within 24 hours before this hUC-MSCs administration. |
| 12. Participants who have severe intracranial hemorrhage grade 3 or active pneumorrhagia or active air leak syndrome. |
| 13. Participants who are using hormones or needing hormones within and after 7 days of hUC-MSCs administration. |
| 14. Participants who are participating in other interventional clinical trials. |
| 15. Participants who is inappropriate considered by the investigators or whose parents can’t afford informed consent. |
| Items                                                                 | Screening phase | Treatment phase |
|----------------------------------------------------------------------|-----------------|-----------------|
|                                                                      | -2w             | Baseline        |
|                                                                      |                 | 24h             |
|                                                                      |                 | 3d              |
| Therapy hUC-MSCs                                                      | √               | √               |
| Traditional treatment                                               | √               | √               | √               |
| Informed consent                                                     | √               |                 |
| Inclusion and exclusion criteria                                     | √               | √               |
| Demographic information                                             | √               |                 |
| Personal history / past history / family history                     | √               |                 |
| Height/weight/head circumference                                     | √               | √               |
| Vital signs*/Physical examination                                    | √               | √               | √               |
| Hematology$ / Blood biochemistry%/Urinalysis®                       | √               | √               |                 |
| Infectious Diseases related examination*                            | √               | √               |                 |
| Blood oxygen saturation / blood gas analysis                         |                 | √               | √               |
| Chromosome examination                                              | √               |                 |
| Brain MRI examination                                                | √               |                 |
| EKG                                                                  | √               | √               |                 |
| Echocardiogram                                                       |                 |                 |
| Ventilator parameters/oxygen therapy                                 | √               | √               | √               |
| Adverse events evaluation                                            | √               | √               |                 |
| Chest high resolution CT                                             | √               |                 |
| Pulmonary function test                                              |                 |                 |
| Mortality/Complications of prematurity##                              |                 |                 |

#: The indicators of vital signs include temperature, blood pressure, heart rate, respiratory rate, transcutaneous oxygen saturation.

$: The condition of hematological participants will be estimated by Hematological Tests which contains white blood cell count, platelet count, red blood cell count, hemoglobin, the percentage of lymphocytes, the percentage of neutrophil and C-reactive protein (CRP).

%: The items of blood biochemistry include liver function, renal function, cardiac markers, the indicators of immunity, and the detailed items of each test are listed as follow. Liver Function Tests: albumin, bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, prothrombin time, activated partial thromboplastin time. Renal Function Tests: creatinine, blood urea nitrogen, creatinine clearance, glomerular filtration rate. Cardiac markers: hypersensitive troponin I, CK-MBmass, myoglobin.

*: Infectious Diseases related examination include markers of Hepatitis / Syphilis / HIV / Tuberculosis.

@: The content of Urinalysis includes pH, protein, specific gravity, glucose and ketone body, white blood cells, occult blood or red blood cells, nitrite, color and turbidity.

##: Complications of prematurity include growth retardation or retardation, hearing abnormalities, retinopathy, pulmonary hypertension, left ventricular hypertrophy.
### Table 3. Outcome measures

| Measures                                                                 | Primary outcomes                                                                 | Adverse events                                                                 |
|-------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Cumulative duration of oxygen therapy                                   | Number of serious adverse events                                                 | Acute infusion associated adverse events                                    |
|                                                                        | Duration of invasive mechanical ventilation                                      | Late infusion associated adverse events                                    |
|                                                                        | Duration of noninvasive mechanical ventilation                                   |                                                                                |
|                                                                        | The first time of stopping oxygen supplement                                     |                                                                                |
|                                                                        | The rate of re-oxygen supplement                                                  |                                                                                |
|                                                                        | Pulmonary function changes                                                        |                                                                                |
|                                                                        | Chest radiography changes                                                        |                                                                                |
|                                                                        | Blood oxygen saturation                                                           |                                                                                |
|                                                                        | Mortality                                                                        |                                                                                |
|                                                                        | Times of hospital readmissions                                                    |                                                                                |
|                                                                        | Complications of preterm birth                                                    |                                                                                |

### Table 4. The telephone follow-up list
| Items | Name: | Age: |
|-------|-------|------|
| Survival status: | | |

| Growth and development | Weight: | Height: |
|-------------------------|---------|---------|

| Numbers of upper respiratory infection | Numbers of pneumonia | Pathogen: |
|----------------------------------------|-----------------------|-----------|
| Numbers of readmission caused by upper respiratory infection | Length of hospital stay, days |

| Oxygen therapy | Steroid use | Bronchodilators |
|----------------|-------------|-----------------|
| □ No | □ No | □ No |
| □ Yes | □ Yes | □ Yes |

| Numbers of pneumonia | Pathogen: |
|-----------------------|-----------|
| Numbers of readmission caused by upper respiratory infection | Length of hospital stay, days |

| Dyspnea assessment and its grade |
|----------------------------------|
| □ No dyspnea |
| □ Mild dyspnea: Only breathing faster or cyanosis when sucking milk, crying, after activity. |
| □ Moderate dyspnea: Breathing is obviously accelerated. The Patient has shoulder lifts, three concave signs and nodding breaths. The lips are blue and irritated, but the symptoms can be improved after oxygen therapy. |
| □ Severe dyspnea: The above performances are aggravated, and respiratory failure, often accompanied by cardiac insufficiency. |

---

**Table 5. The outpatient follow-up list**

| Personal information | Name: | Age: |
|----------------------|-------|------|
| Survival status:     | | |

| Growth and development | Weight: | Height: |
|-------------------------|---------|---------|

| Numbers of upper respiratory infection | Numbers of pneumonia | Pathogen: |
|----------------------------------------|-----------------------|-----------|
| Numbers of readmission caused by upper respiratory infection | Length of hospital stay, days |

| Oxygen therapy | Steroid use | Bronchodilators |
|----------------|-------------|-----------------|
| □ No | □ No | □ No |
| □ Yes | □ Yes | □ Yes |

| Dyspnea assessment and its grade |
|----------------------------------|
| □ No dyspnea |
| □ Mild dyspnea: Only breathing faster or cyanosis when sucking milk, crying, after activity. |
| □ Moderate dyspnea: Breathing is obviously accelerated. The Patient has shoulder lifts, three concave signs and nodding breaths. The lips are blue and irritated, but the symptoms can be improved after oxygen therapy. |
| □ Severe dyspnea: The above performances are aggravated, and respiratory failure, often accompanied by cardiac insufficiency. |

| Physical examination |
|----------------------|
| □ Normal □ Abnormal |

| Accessory examination |
|-----------------------|
| Blood gas analysis |
| Chest high resolution CT |
| Pulmonary function test |
| Brain MRI examination |

---

Additional File
Additional file 1: SPIRIT checklist: recommended items to address in a clinical trial protocol and related documents. (DOCX, 122 kb)

Figures

**Figure 1.** Study flow diagram

![Study Flow Diagram](image-url)
This is a list of supplementary files associated with the primary manuscript. Click to download.

Spirit checklist .doc